YD Bio Ltd. (NASDAQ: YDES):
Advancing a Data-Driven Oncology Platform Spanning Early Cancer-Detection, Clinical Data, and Ocular Healthrgeting Early Cancer Detection and Ocular Health
Download The Corporate Presentation
With U.S.-based cancer diagnostics, FDA-cleared eye care products, and a proposed merger with EG BioMed, YDES is advancing toward a fully integrated biotech platform!
YD Bio Ltd. isn’t a concept-stage biotech company. YDES is already commercializing non-invasive cancer diagnostics and FDA-cleared eye care solutions, while expanding its footprint across the U.S. and international markets.
With a proposed merger with EG BioMed to deepen its oncology platform, hospital-level clinical adoption underway, and multiple clinical programs advancing toward IND submissions, YDES is emerging as a commercial-stage biotech focused on execution, scale, and real-world impact.
THE TOP REASONS TO HAVE YDES ON YOUR RADAR:
- Commercial-Stage Biotech: YDES is already generating revenue across diagnostics, eye care products, and clinical trial drug distribution, setting it apart from many biotech peers, years away from commercialization.
- Proposed EG BioMed Merger: In January 2026, YDES entered a non-binding MOU to merge with Eg BioMed, a move that could integrate DNA methylation diagnostics, real-world clinical data, and AI-driven biomarker analytics into a single oncology platform.
- Cancer Testing Platform Expanding: YDES has expanded its OkaiDx™ blood-based diagnostics to pancreatic and colorectal cancer detection across 44 states, transforming its early cancer detection technology into a scalable U.S. testing platform.
- U.S.-Based Diagnostics: YDES operates through a CAP-accredited, CLIA-certified laboratory in the U.S., enabling commercial testing and a scalable pathway for expanded market coverage.
- Long-Term Strategic Partnerships: YDES has entered 20-year strategic agreements with EG Biomed and 3D Global Biotech, providing exclusive access to advanced diagnostics and regenerative medicine technologies.
- FDA-Cleared Eye Care Products: With Exovisse contact lenses and eye care solutions already on the market, YDES benefits from near-term revenue while advancing higher-value regenerative therapies.
- Hospital Adoption in Asia: EG BioMed’s cancer detection platform has been approved for clinical adoption at three affiliated medical centers of Taipei Medical University and is being integrated into hospital workflows.
- Diversified Platform: YDES spans cancer diagnostics, ocular health, regenerative medicine, and wellness, reducing reliance on a single asset or clinical outcome.
- Additional Revenue Streams: YDES generates revenue through clinical trial drug distribution for pharma and research partners and science-backed health supplements sold in Asia, reinforcing its execution capabilities and diversified business model.
- Advancing Clinical Programs: YDES is advancing multiple ophthalmology and oncology programs toward IND submissions and first-in-human clinical trials, supporting its move from platform validation to clinical execution.
- Positioned in Global Markets: By targeting cancer diagnostics and eye health, YDES is addressing multi-billion-dollar markets driven by rising demand for non-invasive, precision healthcare solutions.
- Robust Patent Portfolio: With 11 licensed patents and 12 pending worldwide, YDES is building robust IP across diagnostics and regenerative healthcare.
Together, these factors position YDES as a commercial-stage biotech evolving into a data-driven oncology and ocular health platform with multiple paths to growth.
A Commercial Biotech Platform Focused on Early Detection and Ocular Health
YD Bio Ltd. (NASDAQ: YDES) has built its foundation as a healthcare company operating at the intersection of diagnostics, eye care, and regenerative medicine.
For years, YDES has worked behind the scenes supporting global pharmaceutical and clinical trial efforts, supplying regulated medical products, diagnostics, and trial drug distribution across international markets. This has allowed YDES to generate revenue, build regulatory infrastructure, and establish long-standing industry relationships.
Today, YDES is applying that experience to higher-growth opportunities in healthcare — starting with non-invasive cancer detection and advanced ocular health solutions. Through U.S.-based laboratory diagnostics and FDA-cleared eye care products already on the market, YDES is moving beyond services into scalable healthcare platforms with long-term upside.
The mission: to make earlier cancer detection and next-generation eye care more accessible through precision diagnostics and innovative therapies that improve outcomes and expand treatment options.
By commercializing early detection and ocular health, YDES is unlocking real-world healthcare demand at scale!
Powering Early Cancer Detection Through EG Biomed
Built on advanced molecular science and real-world diagnostics infrastructure, YDES's partnership with EG Biomed is at the center of the company’s push into early cancer detection, one of healthcare’s most urgent and fastest-growing needs!
EG Biomed is a biotechnology company focused on DNA methylation–based, blood-based cancer detection and monitoring, using liquid biopsy technology to identify cancer signals earlier, less invasively, and with greater precision than traditional approaches.
Turning Liquid Biopsy into a Nationwide Testing Platform:
At the core is OkaiDx™, a blood-based cancer testing platform designed to support both early detection and post-treatment monitoring. Originally launched for breast cancer monitoring, OkaiDx has now evolved to include pancreatic and colorectal cancer detection, broadening its clinical scope!
Today, OkaiDx testing is available across 44 U.S. states through EG Biomed’s CAP-accredited, CLIA-certified laboratory in Washington, supported by:
- A nationwide telehealth physician network for test authorization and follow-up
- An at-home blood collection partner, streamlining access for patients and research collaborators
Early Detection of Cancer:
- Pancreatic cancer: One of the deadliest cancers, often diagnosed too late
- Colorectal cancer: A major cause of cancer-related deaths, yet highly treatable when caught early
- Breast cancer monitoring: Supporting long-term care, recurrence detection, and treatment response
YDES and EG Biomed have entered new agreements with medical groups, integrating OkaiDx testing into primary care and women’s health settings — moving early detection closer to everyday clinical use!
Clinical Data:
Beyond access and scale, the platform is backed by clinical research. In an ongoing EG Biomed–led study of the OkaiDx Detect Pancreatic Cancer Test, it showed:
- 93.8% sensitivity in early-stage (Stage I–II) pancreatic cancer
- 100% sensitivity in late-stage pancreatic cancer
- 97.3% specificity in healthy individuals
- 97.7% overall accuracy across a large patient cohort
These results demonstrate the potential of cfDNA methylation biomarkers to detect pancreatic cancer at stages when treatment options are more effective — a key driver of demand for next-generation diagnostics.
With a 20-year strategic agreement, expanding test availability, and growing clinical validation, the EG Biomed partnership provides YDES with a real diagnostics engine positioned at the heart of the early cancer detection movement!
Expanding Into Ocular Health and Regenerative Medicine With 3D Global Biotech
YDES partnership with 3D Global Biotech powers ocular health and regenerative medicine — a massive, underserved market driven by aging populations, digital eye strain, and chronic inflammatory eye conditions.
3D Global Biotech specializes in eye care products and stem cell–derived exosome therapies, combining commercial medical devices with longer-term regenerative treatments designed to go beyond symptom management.
Through this partnership, YDES gains access to FDA-cleared eye care products already on the market, alongside a pipeline of next-gen therapies targeting chronic and treatment-resistant eye diseases!
From Everyday Eye Care to Advanced Regenerative Solutions:
The collaboration with 3D Global Biotech covers both near-term commercialization and long-term therapeutic innovation.
YDES markets FDA-cleared eye care products, including Exovisse® Contact Lenses and Exovisse Artificial Tears, addressing the growing demand for comfort, safety, and daily usability among millions of eye care patients worldwide.
Exovisse® Contact Lenses recently received FDA 510(k) clearance in the U.S. as a Class II device, and Exovisse Artificial Tears are compliant with FDA OTC monograph standards, allowing broader commercial distribution across the American ophthalmology market!
The partnership is also advancing limbal stem cell–derived exosome therapies — a regenerative approach designed to repair tissue, reduce inflammation, and restore ocular surface health at a cellular level.
What They Target and Why It Matters:
The 3D Global Biotech platform focuses on eye conditions that are chronic, recurring, and often underserved, including:
- Dry eye disease: Affecting hundreds of millions globally, driven by screen use, aging, and environmental stress
- Corneal damage and inflammation: Including post-surgical recovery and injury-related conditions
- Treatment-resistant ocular disorders: Where conventional drops and medications fall short
Why this matters: eye care is no longer a niche market! As visual health becomes a quality-of-life priority, demand is shifting toward solutions that offer lasting relief and tissue repair, not just temporary symptom control.
For YDES, the 3D Global Biotech partnership provides:
- A 20-year exclusive agreement, securing long-term access to proprietary eye care and regenerative technologies
- Commercial products already generating revenue,
- A robust pipeline, targeting unmet needs in ocular health
Global scalability, with applications across consumer eye care, clinical use, and specialty treatment
By combining FDA-cleared products, advanced regenerative science, and long-term exclusivity, the partnership with 3D Global Biotech gives YDES a foothold in a market where innovation, scale, and demand are colliding!
MOMENTUM & MILESTONES:
From expanding its U.S. diagnostics footprint to advancing multiple clinical programs, YD Bio Ltd. (NASDAQ: YDES) is actively moving from strategy to execution.
- Proposed EG BioMed Merger: In January 2026, YDES entered into a non-binding MOU to merge with EG BioMed, marking a key step toward building a fully integrated, data-driven oncology platform.
- Hospital-Level Clinical Adoption: EG BioMed’s DNA methylation cancer detection platform has been approved for clinical adoption at three affiliated medical centers of Taipei Medical University and is being integrated into hospital workflows.
- Expanded U.S. Cancer Diagnostics Platform: Through EG BioMed, YDES operates CLIA- and CAP-certified cancer diagnostics across 46 U.S. states under its OkaiDx™ platform, supporting commercial testing and real-world data generation.
- FDA-Aligned Oncology Validation: The OkaiDx™ pancreatic cancer early detection program is progressing through an FDA-aligned validation pathway, with patient enrollment completion and an FDA Q-Submission planned in 2026.
- Ophthalmology Clinical Programs Advancing: YDES plans to submit IND applications in 2026 for limbal stem cell–derived exosome therapies targeting dry eye disease and age-related macular degeneration, with first-in-human trials expected to begin in 2027.
- Taiwan TFDA Clinical Validation Underway: Enrollment is expected to begin in 2026 for a TFDA-regulated clinical program evaluating LSC exosome eye drops for dry eye symptoms, providing first-in-human validation to support future U.S. FDA development.
- Regulatory De-Risking Achieved: The company has filed Drug Master Files (DMFs) with the FDA for both limbal stem cells and limbal stem cell–derived exosome products, establishing a reusable regulatory foundation for future IND submissions.
Together, these milestones point to a biotech company moving from setup to execution, with multiple initiatives advancing at the same time!
THE MARKET OPPORTUNITY:
🧬 Global Cancer Diagnostics Market: Estimated to reach $178+ billion by 2033, driven by rising cancer incidence and demand for earlier, more precise detection.
🩸 Liquid Biopsy & Molecular Diagnostics: One of the fastest-growing segments in diagnostics as healthcare systems shift toward non-invasive, blood-based testing.
🎯 Pancreatic Cancer Diagnostics: Global market projected at $4.7 billion, with U.S. demand alone expected to exceed $2.4 billion, fueled by urgent need for earlier detection.
🎗️ Breast Cancer Diagnostics: Global market projected at $9.5 billion, with continued growth driven by long-term monitoring and recurrence detection.
👁️ Global Eye Care Market: Projected to exceed $100 billion by 2030, spanning contact lenses, dry eye treatments, and therapeutic eye care solutions.
💧 Dry Eye Disease Market: Expected to reach $13 billion globally, driven by aging populations, screen exposure, and chronic inflammation.
👓 Contact Lens Market: Over 140 million users worldwide, representing a massive, recurring, consumer-driven healthcare market.
🔬 Regenerative Eye Therapies: Emerging, high-value segment focused on tissue repair and long-term treatment of chronic ocular conditions.
Why YDES Is Positioned to Benefit: YDES operates across multiple areas of these markets — from commercial diagnostics and FDA-cleared eye care products available today, to next-generation regenerative therapies designed for long-term growth!
With exposure to early cancer detection and ocular health, YDES is positioned at the center of two of healthcare’s fastest-growing markets!
THE BOTTOM LINE
YD Bio Ltd. (NASDAQ: YDES) isn’t chasing a single area— it’s building a multi-engine healthcare platform positioned at the intersection of early cancer detection, ocular health, and regenerative medicine.
YDES achieved a significant milestone by entering into a non-binding MOU to merge with EG BioMed. Through EG Biomed, YDES is entering one of healthcare’s most urgent needs: detecting cancer earlier, faster, and less invasively.
In addition YDES’ collaboration with 3D Global Biotech combines 78 FDA-cleared eye care products already available with next-generation regenerative therapies designed for long-term impact.
What sets YDES apart is execution. This is not a pre-revenue biotech waiting on a single approval. YDES already operates commercial diagnostics in the U.S., sells regulated eye care products, and generates revenue across multiple healthcare segments, all while advancing to a more robust pipeline.
The timing matters. Cancer diagnostics is a hundreds-of-billions-dollar global market shifting rapidly toward liquid biopsy and molecular testing. Eye care and ocular therapeutics are another massive, growing opportunity, driven by aging populations, chronic conditions, and rising demand for better long-term solutions.
With long-term strategic partnerships, a growing global patent portfolio, and exposure to healthcare markets built on necessity — not hype — YDES is positioning itself for scale in areas where demand is durable, and innovation is growing!
As healthcare continues its shift toward earlier detection, non-invasive care, and regenerative solutions, YDES is emerging as a company investors will want to watch — one with real platforms, real markets, and multiple paths to growth!
Discover how YD Bio Ltd. (NASDAQ: YDES) is building a diversified biotech platform across diagnostics, eye care, and regenerative medicine.
Learn More about YD Bio Ltd. by gaining access to the latest corporate presentation
Download PRESENTATIONTHIS IS A PAID ADVERTISEMENT
NO INVESTMENT ADVICE
This website provides information about the stock market and other investments. This website does not provide investment advice and should not be used as a replacement for investment advice from a qualified professional. This website is for informational purposes only. The Author of this website is not a registered investment advisor and does not offer investment advice. You, the reader, bear responsibility for your own investment decisions and should seek the advice of a qualified securities professional before making any investment. Nothing on this website should be considered personalized financial advice. Any investments recommended here in should be made only after consulting with your personal investment advisor and only after performing your own research and due diligence, including reviewing the prospectus or financial statements of the issuer of any security.
SCD Media, its managers, its employees, affiliates, and assigns (collectively "The Company") do not make any guarantee or warranty about the advice provided on this website or what is otherwise advertised above. To the maximum extent permitted by law, the Company disclaims all liability in the event any information, commentary, analysis, opinions, advice and/or recommendations provided herein prove to be inaccurate, incomplete, or unreliable, or result in any investment or other losses.
You received this message as part of your subscription to SCD Alerts.
SCD Alerts is a financial news and information website. We do not directly sell any products or offer any personal financial advice, nor do we advocate the purchase or sale of any security or investment for any specific individual. We also do not make any guarantee or warranty about what is advertised above.
If you have questions or concerns about a product you’ve seen in one of our emails, we encourage you to reach out to that company directly. Disclaimer – Always do your own research and consult with a licensed investment professional before investing. This communication is never to be used as the basis of making investment decisions and is for entertainment purposes only. At most, this communication should serve only as a starting point to do your own research and consult with a licensed professional regarding the companies profiled and discussed. Conduct your own research. This newsletter is a paid advertisement, not a recommendation nor an offer to buy or sell securities. This newsletter is owned, operated, and edited by SCD Media. Any wording found in this e-mail or disclaimer referencing “I” or “we” or “our” or “SCD” refers to SCD Media. Our business model is to be financially compensated to market and promote small public companies. By reading our newsletter and our website you agree to the terms of our disclaimer, which are subject to change at any time. We are not registered or licensed in any jurisdiction whatsoever to provide investing advice or anything of an advisory or consultancy nature and are therefore unqualified to give investment recommendations. Companies with low prices per share are speculative and carry a high degree of risk, so only invest what you can afford to lose. By using our service, you agree not to hold our site, its editor’s, owners, or staff liable for any damages, financial or otherwise, that may occur due to any action you may take based on the information contained within our newsletters or on our website. We do not advise any reader to take any specific action. Losses can be larger than expected if the company experiences any problems with liquidity or wide spreads. Our website and newsletter are for entertainment purposes only.